BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The  company  Amgen  Europe  B.V.  submitted  on  23  June  2000  an  application  for  Marketing 
Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for 
Kineret/Amceptor, in accordance with the centralised procedure falling within the scope of Part A of 
the Annex to Council Regulation No (EEC) 2309/93 of 22 July 1993. 
The Rapporteur and Co-Rapporteur appointed by the CPMP were: 
Rapporteur:  Dr. M. A. Ainsworth 
Co-Rapporteur: 
Prof. Cristina Sampaio 
Licensing status: 
Kineret has been given a Marketing Authorisation in USA on 14 November 2001. 
The product was not licensed in any country at the time of submission of the application. 
2. 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
Steps taken for the assessment of the product 
The procedure started on 18 July 2000. 
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on 
2 October 2000.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP 
members on 29 September 2000. 
During  the  meeting  on  14-16  November  2000  the  CPMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 16 November 2000. 
The  company  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on 
17 May 2001 and 4 July 2001 
The summary report of the inspection  carried out at the manufacturing site between 2-5 April 
2001  of  the  active  substance  manufacturing  site  (Amgen  Inc.,  Boulder,  Colorado,  USA)  was 
issued on 24 August 2001. 
The  Rapporteur/Co-Rapporteur  circulated  the  draft  response  Assessment  Report  on  the 
company’s responses to the List of Questions to all CPMP members on 5 July 2001. 
During the CPMP meeting on 25-27 July 2001, the CPMP adopted a list of outstanding issues to 
be addressed during an oral explanation. 
The  Rapporteur’s  Assessment  Report  on  the  company’s  responses  to  the  List  of  outstanding 
issues was circulated to all CPMP members on 9-10 October 2001. 
During  the  CPMP  meeting  on  16-18  October  2001,  the  outstanding  issues  were  addressed  by 
the applicant during a hearing before the CPMP. 
Following the oral explanation, the applicant withdrew on 6 November 2001 the application for 
Amceptor. The marketing authorisation is only sought for Kineret 100 mg solution for injection 
in prefilled syringe and in vial.  
The  Rapporteur’s  Assessment  Report  on  the  company’s  responses  to  remaining  issues  to  be 
solved before Opinion was circulated to all CPMP members on 8 November 2001. 
During  the  meeting  on  13-15  November  2001  the  CPMP,  in  the  light  of  the  overall  data 
submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for 
granting a Marketing Authorisation to Kineret on 15 November 2001. 
1/1 
EMEA 2004 
 
 
 
 
 
 
